▲ Peaking
Business
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
Bristol Myers Squibb secures pivotal Phase 3 wins in lung disease and solid tumors, sparking complex market reactions.